BLOOM Test Results Revealed

Tokyo’s Eisai Co Ltd, with its United States subsidiary Eisai Inc and Arena Pharmaceuticals Inc, recently announced its disclosure of the test results from the Behavioral Modification and Lorcaserin for Overweight and Obesity Management, or BLOOM, trial.

Lorcaserin is a new drug for treating weight management and obesity. Arena Pharmaceuticals Inc subsidiary Arena Pharmaceuticals GmbH provided Eisai Inc the exclusive rights to promote and sell the drug in America. According to the data presented, the drug caused subjects to lose weight better and improve weight loss management as opposed to placebo. Lorcaserin likewise increased values for biomarkers that could be predictive of impending cardiovascular occurrences, such as insulin resistance, blood pressure, lipid levels and inflammatory markers levels.

The random trial was a double-blind, placebo-controlled testing, examining 3,182 overweight and obese patients. During the first year, the number of patients losing at least 5% of body weight using the drug was twice more than what was attained by the other group that took placebo. There were about three times as much lorcaserin subjects achieving 10% in weight loss than in the placebo subjects. By the second year, subjects continuing to take the drug were able to maintain their weight compared to those who were switched to placebo.

Esai is dedicated to improving the lives of its patients and their families by meeting the issues concerning their medical needs. Not only will the locaserin drug give the company an opportunity to offer patients a new weight management treatment alternative, it will likewise allow it to provide more contributions in treating obesity.